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Abstract
G protein-coupled P2Y receptors (P2Y-R) are activated by adenine and uracil nucleotides. The
P2Y14 receptor (P2Y14-R) is activated by at least four naturally occurring UDP sugars, with UDP-
glucose (UDP-Glc) being the most potent agonist. With the goal of identifying a competitive
antagonist for the P2Y14-R, UDP was examined for antagonist activity in COS-7 cells transiently
expressing the human P2Y14-R and a chimeric Gα protein that couples Gi-coupled receptors to
stimulation of phosphoinositide hydrolysis. UDP antagonized the agonist action of UDP-Glc, and
Schild analysis confirmed that the antagonism was competitive (pKB = 7.28). Uridine 5′-O-
thiodiphosphate also antagonized the human P2Y14-R (hP2Y14-R) with an apparent affinity
similar to that of UDP. In contrast, no antagonist activity was observed with ADP, CDP, or GDP,
and other uracil analogs also failed to exhibit antagonist activity. The antagonist activity of UDP
was not observed at other hP2Y-R. In contrast to its antagonist action at the hP2Y14-R, UDP was a
potent agonist (EC50 = 0.35 μM) at the rat P2Y14-R. These results identify the first competitive
antagonist of the P2Y14-R and demonstrate pharmacological differences between receptor
orthologs.
P2Y receptors (P2Y-R) are members of the superfamily of G protein-coupled receptors
(GPCRs) and are activated by adenine and uridine nucleotides and nucleotide sugars. Atleast
eight receptors comprise the P2Y-R family. P2Y1, P2Y2, P2Y4, and P2Y6 receptors are
coupled to Gq and activate phospholipase C, whereas P2Y12, P2Y13, and P2Y14 receptors
couple to Gi, leading to the inhibition of adenylyl cyclase and activation of ion channels
(Burnstock, 2006). The P2Y11-R uniquely couples both to Gq to activate phospholipase C
and to Gs to stimulate adenylyl cyclase (Communi et al., 1997; Qi et al., 2001).
The human P2Y14-R (hP2Y14-R) was identified as the eighth legitimate member of the P2Y
receptor family (Chambers et al., 2000). UDP-glucose (UDP-Glc) was proposed to be the
endogenous agonist for the P2Y14 receptor (P2Y14-R), with UDP-galactose, UDP-
glucuronic acid, and UDP-N-acetylglucosamine acting as less potent P2Y14-R agonists.
P2Y14-R mRNA was detected in a broad range of human tissues including placenta,
stomach, intestine, adipose, brain, lung, spleen, and heart, and it was also found in
specialized cells such as circulating neutrophils (Chambers et al., 2000; Scrivens and
Dickenson, 2006). The rat and mouse P2Y14-R exhibit 80 and 83% amino acid identity to
the human receptor, and both rodent orthologs are activated by known agonists with a
similar profile to that of the hP2Y14-R (Freeman et al., 2001).
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Cellular UDP-Glc is released in a constitutive manner into the medium of a broad range of
cell types. Although most extracellular nucleotides are metabolized quickly, UDP-Glc
accumulates in the medium of several cell lines (Lazarowski et al., 2003). The mechanisms
of UDP-Glc release and extracellular metabolism remain unclear. Observations of UDP-Glc-
promoted signaling were reported in multiple types of immune cells (Fumagalli et al., 2003;
Skelton et al., 2003; Müller et al., 2005; Scrivens and Dickenson, 2005), suggesting that the
P2Y14-R may have a yet-to-be-defined role in the regulation of immune system
homeostasis.
Characterization of the P2Y14-R has been slowed by the lack of a selective competitive
antagonist. We have identified and developed novel, selective ligands for several P2Y
receptors that have proven useful for pharmacological resolution of molecularly defined
P2Y-R in cells and tissues (Boyer et al., 1996; Houston et al., 2006, 2008; Jacobson et al.,
2006). Accordingly, we are interested in identifying a selective antagonist for the P2Y14-R.
Ault and Broach (2006) recently used a yeast model system in which various nucleotides
and nucleotide sugars were examined for their ability to stimulate growth of mutant P2Y14-
R-expressing yeast cells in studies focused on the identification of mutant P2Y14 receptors
with differential agonist sensitivities. Studies performed using one of these mutant receptors
revealed that UDP antagonized UDP-Glc-promoted receptor activation in a concentration-
dependent manner (Ault and Broach, 2006). We hypothesized that UDP acts as a
competitive antagonist at the wild-type P2Y14-R and, therefore, used a transfected COS-7
cell system to investigate UDP activity at the human and rat P2Y14-R. In this study, we
show that UDP is a selective and competitive antagonist of the hP2Y14-R. Thus, signals
emanating from extracellular UDP apparently occur as a consequence of activation of the
P2Y6-R as well as through antagonism of the P2Y14-R. We were surprised to find that UDP
is a potent full agonist at the rat P2Y14-R.
Materials and Methods
Materials
UDP-Glc, UDP, ADP, CDP, GDP, and 2-methyl-thio-ADP were purchased from Sigma-
Aldrich (St. Louis, MO). Diuridine 5′,5′-triphosphate (UP3U) was synthesized according to
the methods detailed in Pendergast et al. (2001). The source of diuridine 5′,5′-tetraphosphate
(UP4U) was as previously reported (Ivanov et al., 2007). ATP and UTP were purchased
from GE Healthcare (Piscataway, NJ). [32P]PPi was synthesized as described previously
(Lazarowski et al., 2003). Uridine 5′-O-thiodiphosphate (UDPβS) as well as a mammalian
expression vector for ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) were
generous gifts from Dr. José Boyer of Inspire Pharmaceuticals (Durham, NC).
Cell Culture and Transfection
COS-7 cells were grown on 12-well culture dishes and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 4 mM L-
glutamine at 37°C in a 10% CO2 environment. FuGENE 6 (Roche Applied Science,
Indianapolis, IN) was used as the transfection reagent following the manufacturer’s protocol.
Cells were transfected 48 h before assay with pcDNA3.1 expression vectors encoding either
the human or rat P2Y14 receptor with an N-terminal hemagglutinin epitope tag. The
expression vector for the hP2Y14-R was obtained as reported previously (Lazarowski et al.,
2003). Transfections also included pcDNA3.1-Gαq/i, a vector that directs expression of a
chimera of Gαq containing the last five amino acids of Gαi. This chimeric G protein
promotes activation of phospholipase C through Gαi-coupled receptors (Coward et al.,
1999). The levels of basal inositol phosphates increased markedly in COS-7 cells upon
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expression of human or rat P2Y14-R and Gαq/i. Because we previously illustrated that UDP-
sugars are basally released by various cell types (Lazarowski et al., 2003), in some
experiments pcDNA3.1-expressing ENPP1 was cotransfected with the goal of hydrolyzing
extracellular nucleotide sugars and potentially decreasing inositol phosphate accumulation in
the absence of added P2Y14-R agonists.
Inositol Phosphate Accumulation Assay
Cells were labeled 8 to 18 h before assay with 0.5 to 3 μCi/well myo-[3H]inositol (American
Radiolabeled Chemicals, St. Louis, MO) in inositol-free and serum-free DMEM. Assays
were initiated with the addition of 10 mM LiCl with or without drugs, and incubations
continued for 45 min at 37°C. Reactions were stopped by aspiration of medium and addition
of ice-cold 50 mM formic acid. After neutralization with 150 mM ammonium hydroxide,
[3H]inositol phosphates were isolated by Dowex column chromatography as described
previously (Nakahata and Harden, 1987). Stable cell lines for P2Y1, P2Y2, P2Y4, P2Y6, or
P2Y11 receptors were generated in 1321N1 human astrocytoma cells as described previously
(Nicholas et al., 1996; Kennedy et al., 2000). Experiments testing the potential activity of
UDP at the P2Y2-R and P2Y4-R included hexokinase to eliminate contamination of UTP as
previously described in Nicholas et al. (1996). In brief, UDP was treated with 10 U/ml
hexokinase in the presence of 22 mM glucose for 1 h at 37°C, and 1 U/ml hexokinase was
included in the assay buffer for the duration of the incubation. Variability in cpm of [3H]-
inositol phosphate accumulation across experiments occurred due to differences in the
amount of [3H]inositol used for labeling and/or the duration of the prelabeling period.
Measurement of UDP-Glc in the Cell Medium
Quantification of UDP-Glc was performed as described previously (Lazarowski et al.,
2003). In brief, incubations were in a final volume of 150 μl containing known or unknown
amounts of UDP-Glc, 25 mM HEPES, pH 7.4, 0.5 U/ml UDP-glucose pyrophosphorylase
from baker’s yeast (Sigma-Aldrich), and 100 nM [32P]PPi (200,000 cpm). Incubations were
terminated by addition of 0.3 mM PPi and immediate heating of samples for 2 min at 95°C,
and formation of [32P]UTP was quantified by high-performance liquid chromatography as
described previously (Lazarowski et al., 2003).
Quantification of P2Y14-R Expression
Cells were seeded in 12-well plates at 5 × 104 cells/well 3 days before assay and transfected
with mammalian expression vectors as described above. Cells were fixed with 0.4 ml of 4%
paraformaldehyde for 30 min at room temperature, washed twice with 1 ml of Hanks’
balanced salt solution plus Ca2+/Mg2+, and incubated for 30 min at room temperature with
0.4 ml of DMEM plus 50 mM HEPES, pH 7.1, and 10% fetal bovine serum. Cells were
incubated with mouse HA.11 monoclonal antibody at a 1:1000 dilution in 0.4 ml of medium
for 1 h at room temperature. After two washes with 1 ml of Hanks’ balanced salt solution
plus Ca2+/Mg2+, cells were incubated with [125I]rabbit anti-mouse IgG antibody diluted to
1:500 in 0.4 ml of medium for 2 h at room temperature. After another series of washing
steps, cells were solubilized in 0.4 ml of 1 M NaOH overnight and transferred to glass tubes
for quantification of radioactivity in a gamma counter.
Rat P2Y14-R Subcloning
The rat homolog of the P2Y14-R (rP2Y14-R) was amplified from rat genomic DNA using
Pfu polymerase (Stratagene, Carlsbad, CA) with the following primers: (5′-
GAGACGCGTCCGACAACACAACAACCACAGAAC-3′) and (5′-
AGACTCGAGTTACAAAGTATCTGTGCTTTCC-3′). The primers contained either a
MluI (upstream primer) or a XhoI (downstream primer) restriction site, respectively (sites
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are underlined), to facilitate cloning. The amplification conditions were as follows: 94°C for
5 min; 35 cycles of 94°C for 45 s, 55°C for 45 s, and 72°C for 90 s; and a final extension for
4 min at 72°C. The amplified rP2Y14-R fragment was digested with MluI and XhoI,
purified, and ligated into a similarly digested, modified pcDNA3 expression vector, which
fuses a hemagglutinin epitope to Asp-2 at the N terminus of the receptor. An individual
clone encoding the receptor was sequenced and found to be identical to the published
sequence (Freeman et al., 2001).
Data Analyses
The results from each experiment are expressed as the mean ± S.E. from triplicate samples
and were analyzed using Prism 4.0 software (GraphPad Software Inc., San Diego, CA). All
experiments were repeated at least three times with similar results. Schild analysis was
performed using EC50 values from the concentration-effect curves for UDP-Glc generated in
the absence and presence of increasing concentrations of UDP. The pKB was calculated
using the equation: log ([A′]/[A] − 1) = log [B] − log pKB (Arunlakshana and Schild, 1959),
where [A′] is the concentration of UDP-Glc necessary to produce 50% of the maximal effect
in the presence of antagonist [B], and [A] is the concentration of agonist necessary to
produce 50% of the maximal effect in the absence of antagonist. Drug response data
presented in Figs. 3A, 5, A–D, and 7B are normalized as a percentage of the response
observed with a maximally effective concentration (usually 10 μM) of UDP-Glc. Statistics
were carried out using the Student’s t test.
Results
Agonist Activity of UDP-Glc at the hP2Y14-R
To assay the functional activity of the hP2Y14-R, we used COS-7 cells transiently
coexpressing the hP2Y14-R and a Gαq/i chimera. The Gαq/i chimera is a Gαq protein in
which the last five amino acids at the C terminus have been substituted with those of Gαi.
This chimeric Gα subunit is activated by GPCRs that couple to the Gαi family of G proteins
and signal through downstream Gαq effectors such as phospholipase C (Coward et al.,
1999). Expression of the hP2Y14-R or the Gαq/i chimera alone in COS-7 cells resulted in
levels of [3H]inositol phosphate accumulation similar to that observed in cells expressing
empty vector alone. [3H]Inositol phosphate accumulation was not changed by the addition of
100 μM UDP-Glc to cells expressing empty vector, the hP2Y14-R, or Gαq/i (Fig. 1).
Coexpression of the hP2Y14-R and Gαq/i resulted in increased [3H]inositol phosphate
accumulation in the presence of buffer alone, as we previously reported (Lazarowski et al.,
2003). Addition of 100 μM UDP-Glc to cells coexpressing the hP2Y14-R and Gαq/i resulted
in a 2-fold increase in inositol phosphate accumulation, consistent with agonist-promoted
activation of phospholipase C (Fig. 1).
To investigate the nature of the hP2Y14-R-dependent [3H]inositol phosphate accumulation
in the absence of added agonist, we coexpressed ENPP1 with the hP2Y14-R and Gαq/i in
COS-7 cells with the goal of removing any released nucleotide/nucleotide sugar potentially
present in the medium. UDP-Glc levels (3.6 ± 1.9 nM) in the bulk medium from COS-7
cells expressing hP2Y14-R and Gαq/i were similar to that of control cells (3.3 ± 0.3 nM). In
contrast, coexpression of ENPP1 in cells also expressing hP2Y14-R and Gαq/i resulted in an
approximately 78% reduction in UDP-Glc levels (0.8 ± 0.5 nM) compared with control
cells. Although expression of ENPP1 alone had no effect on basal [3H]inositol phosphate
accumulation, expression of ENPP1 with hP2Y14-R and Gαq/i resulted in an approximately
40% decrease (p < 0.01) in basal [3H]inositol phosphate levels compared with cells
expressing receptor and G protein alone (Fig. 2A). Expression of ENPP1 had no effect on
surface expression of the hP2Y14-R as quantified with an immunoassay (data not shown; see
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Materials and Methods), and it did not notably change the concentration-effect curve for
added UDP-Glc (Fig. 2B). Thus, we conclude that the hP2Y14-R-dependent elevation of
[3H]inositol phosphate levels in the absence of added agonist occurs largely because of
autocrine/paracrine release of the P2Y14-R agonist. However, these results do not entirely
rule out the possibility that the overexpressed P2Y14-R exhibits constitutive activity in this
test system.
Antagonist Effect of UDP at the hP2Y14-R
Four UDP sugars were identified as agonists at the hP2Y14-R, and neither UTP nor UDP
exhibited agonist activity (Chambers et al., 2000). To determine whether UDP is an
antagonist at the wild-type hP2Y14-R, we generated a series of concentration-effect curves
for UDP-Glc-promoted stimulation of phospholipase C in the presence of increasing
concentrations of UDP (Fig. 3A). UDP caused a parallel rightward shift of the UDP-Glc
concentration-effect curve, and Schild analysis (Fig. 3B) confirmed that the antagonism
produced by UDP was competitive (slope = 1.15 ± 0.06, n = 3). The pKB of UDP for
antagonism of the hP2Y14-R was 7.28 ± 0.04.
We also assessed whether UDP exhibited antagonist activity at other P2Y-R stably
expressed in 1321N1 human astrocytoma cells. P2Y1-R was maximally activated by 1 μM
2MeSADP (Fig. 4A), P2Y2-R and P2Y4-R were each activated by 3 μM UTP (Fig. 4, B and
C), and P2Y11-R was activated by 100 μM ATP (Fig. 4D). Although 10 μM UDP
completely blocked a near-maximal concentration of UDP-Glc at the hP2Y14-R (Fig. 3),
UDP had no effect at any other P2Y receptors tested. Thus, we conclude that UDP is a
selective antagonist at the hP2Y14-R.
To determine whether the antagonist effect of UDP at the hP2Y14-R is specific to the uracil
structure, we also tested other nucleotides and nucleotide derivatives as antagonists at the
hP2Y14-R. In contrast to the action of UDP, other nucleoside diphosphates including ADP,
CDP, and GDP, at concentrations of 10 or 100 μM, did not inhibit UDP-Glc (3 μM)-
promoted [3H]inositol phosphate formation (Fig. 5). We also tested whether other uridine-
based molecules would antagonize activation of the hP2Y14-R by UDP-Glc. Neither UTP,
UP3U, nor UP4U inhibited UDP-Glc activation of the receptor, although each of these
nucleotides, when tested alone, produced a stimulatory effect in untransfected COS-7 cells
(data not shown). The discovery of antagonist activity of UDP at the hP2Y14-R is also
supported by the observation that the UDP analog, UDPβS, inhibited activation of this
receptor by UDP-Glc (Fig. 6). The IC50 observed for UDPβS was similar to that determined
for UDP under the same assay conditions. From these results, we conclude that UDP seems
to be unique among naturally occurring nucleotides in its capacity to inhibit UDP-Glc-
dependent activation of the hP2Y14-R.
Effects of UDP at the rP2Y14-R
Because pharmacological studies are often carried out with rat or mouse tissues, it is
important to assess whether receptor orthologs exhibit pharmacological selectivities similar
to those of human P2Y-R. Based on the precedent that ATP acts as an antagonist at the
human P2Y4-R but is an agonist at the rat P2Y4-R (Bogdanov et al., 1998; Kennedy et al.,
2000), we compared the action of UDP at the rP2Y14-R with its action at the hP2Y14-R. The
rat P2Y14-R, which exhibits approximately 80% amino acid sequence identity to the
hP2Y14-R and almost 90% identity in the transmembrane regions alone, was reported to
display a similar UDP-sugar selectivity to that of the hP2Y14-R (Freeman et al., 2001), but
the actions of other uridine nucleotides on the rP2Y14-R have not been reported.
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Expression of either the rP2Y14-R or Gαq/i in COS-7 cells had no effect on [3H]inositol
phosphate accumulation compared with untransfected cells, but coexpression of receptor and
Gαq/i resulted in markedly increased basal accumulation (Fig. 7A). Consistent with other
reports (Freeman et al., 2001), UDP-Glc was a potent agonist at the rP2Y14-R (Fig. 7B).
Whereas UDP had no effect on inositol phosphate accumulation in wild-type COS-7 cells, in
cells expressing Gαq/i alone, or in cells expressing the rP2Y14-R alone (data not shown),
concentration of UDP-dependent increases in formation of [3H]inositol phosphates occurred
in COS-7 cells coexpressing the rat P2Y14-R with Gαq/i (Fig. 7B). The maximal stimulatory
effect observed with UDP was similar to that observed with UDP-Glc, as were the EC50
values of UDP (0.35 ± 0.17 μM) and UDP-Glc (EC50 = 0.28 ± μM). No additivity was
observed between UDP and UDP-Glc on rP2Y14-R-promoted [3H]inositol phosphate
formation (Fig. 7C).
Discussion
In this study, we show that UDP is a competitive antagonist at the human P2Y14-R, and this
action is receptor-selective because UDP does not inhibit agonist-promoted activation of
other hP2Y receptors. Moreover, the activity of UDP at the P2Y14-R is species-dependent
because we observed that UDP is a potent, and apparently full, agonist at the rat P2Y14-R.
Chambers et al. (2000) reported in their initial study of the hP2Y14-R that UDP has no
agonist activity, and we observed similar results in the studies reported here. Using a
reporter system in yeast, Ault and Broach (2006) generated a mutant hP2Y14-R displaying a
mutation in intracellular loop 1 and various mutations in several of the transmembrane
regions. This mutant, selected for its ability to support growth of yeast at lower
concentrations of UDP-Glc than the wild-type receptor, exhibited an enhanced UDP-Glc-
stimulated response that was inhibited by UDP, and a KB in the micromolar range was
reported. The >20-fold higher potency of UDP observed in our studies probably reflects
large differences in the assay systems used. For example, whereas incubations with
nucleotide were continued for minutes in the current study, they were continued for hours in
assays measuring P2Y14-R-mediated regulation of growth of yeast. Our results illustrate that
UDP is a potent, competitive antagonist of the wild-type hP2Y14-R.
Demonstration of antagonist action at the hP2Y14-R suggests that UDP may have broader
physiological importance as an extracellular signaling molecule than has been previously
appreciated. Both UDP and UDP-glucose are known to be released from cells, although the
mechanisms of their release remain unclear. UDP is the most potent and selective agonist of
the hP2Y6-R (Lazarowski and Harden, 1994; Communi et al., 1996), and physiological
responses attributed to UDP-initiated P2Y6-R-promoted signaling include modulation of
interleukin-8 production in monocytes (Warny et al., 2001) and human mature dendritic
cells (Idzko et al., 2004). In addition, UDP was observed to induce a positive inotropic effect
in mouse cardiomyocytes (Wihlborg et al., 2006) and to promote ion transport in human
placental cytotrophoblast cells (Roberts et al., 2006). Our data indicate that potential
contributions of the P2Y14-R to responses associated with UDP must be considered.
Whereas reported distribution of P2Y6-R mRNA overlaps with that of P2Y14-R mRNA in
many cells and tissues, such as lung, heart, placenta, and neutrophils (Communi et al., 1996;
Moore et al., 2001), it remains unclear whether the two receptor types are coexpressed in the
same cells or in different cells that share the same extracellular space.
The actions of extracellular neurotransmitters and hormones are highly regulated by their
release, metabolism, and reuptake. The possibility that direct antagonism of GPCR
activation occurs by extracellular signaling molecules has been suggested by observations
that ATP is a competitive antagonist of the hP2Y12-R (Cusack and Hourani, 1982; Bodor et
Fricks et al. Page 6













al., 2003) and of the hP2Y4-R (Bogdanov et al., 1998; Kennedy et al., 2000). The
physiological relevance of UDP antagonism at the hP2Y14-R will be important to
investigate, as will the idea that UDP simultaneously activates the hP2Y6-R while inhibiting
the hP2Y14-R.
Our finding that UDP has agonist activity at the rP2Y14-R was surprising. Study of the rat
and human receptors under identical conditions rules out trivial explanations for this
observation. These data do not unambiguously rule out the possibility that UDP is a partial
agonist at the human receptor under some conditions. However, the agonist versus
antagonist action of the nucleotide at the rat versus human P2Y14-R has been observed over
a broad range of expression levels of these two receptors. Our activity data suggest that the
binding affinity of UDP for the human and rat receptors are in fact quite similar, but
development of a radioligand binding assay will be necessary to fully assess this assertion.
The fact that the maximal agonist activity of UDP was similar to that of UDP-Glc over a
broad range of P2Y14-R expression levels (data not shown) suggests that the intrinsic
efficacy of UDP at the rat P2Y14-R is similar to that of UDP-Glc.
The differential activity of UDP observed between the rat and human orthologs of the
P2Y14-R shares similarities to the actions of ATP at the P2Y4-R. Kennedy et al. (2000)
compared the ligand selectivities of the rat and human P2Y4 receptors under conditions that
minimize the effects of released nucleotides and of extracellular bioconversion of
nucleotides, and they observed that ATP is an agonist at the rat P2Y4-R and a competitive
antagonist at the human P2Y4-R. Residues in the second extracellular loop of the P2Y4
receptor are the primary determinants for the agonist versus antagonist activity of ATP
between the two species orthologs (Herold et al., 2004). Like the P2Y4-R, the P2Y14-R
shares approximately 80% amino acid sequence identity between the rat and human
orthologs, with 90% identity when analysis is restricted to transmembrane regions only.
Recent work by Ko et al. (2007) defines the human P2Y14 receptor through structure-
activity studies in conjunction with molecular modeling studies. Residues in the second
extracellular loop of the hP2Y14-R are predicted to interact with the diphosphate moiety and
hydroxyl groups on the hexose ring of UDP-Glc. Comparative modeling of the rat P2Y14-R
and receptor mutagenesis directed from these predictions may identify key domains
responsible for agonist efficacy at the hP2Y14-R.
The mouse P2Y14-R has been cloned and is reported to be activated by the same UDP-sugar
agonists as the human and rat receptors (Freeman et al., 2001). The rat and mouse P2Y14-R
share 89% overall amino acid sequence identity and are essentially identical in their
transmembrane-spanning domains and the second extracellular loop. Thus, we anticipate
that the agonist action of UDP observed with the rat receptor will be similarly observed at
the mouse P2Y14-R.
The finding that UDP acts as a competitive antagonist at the hP2Y14-R provides an excellent
template for rational synthesis of antagonist analogs that exhibit high affinity at the hP2Y14-
R. Our structure-activity studies of UDP analogs at the hP2Y6-R (Besada et al., 2006) also
provide potential avenues for development of P2Y14-R antagonists that do not act as ligands
for the P2Y6-R. Synthesis of a hydrolysis-resistant competitive antagonist for the P2Y14-R
is an obvious goal, as is a high-affinity radiolabeled antagonist.
UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine were
previously identified as full or partial agonists at the human and rodent P2Y14-R (Chambers
et al., 2000; Freeman et al., 2001). The pharmacological selectivity for the P2Y14-R is now
broadened with the finding that UDP also acts at this receptor. The identification of UDP as
a competitive antagonist for the hP2Y14-R provides new insight into the physiological
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regulation of this receptor, and it should be of pharmacological importance in delineating the
functional roles subserved by this signaling protein.
Acknowledgments
We appreciate the excellent technical assistance of Sonia de Castro for the synthesis of UP3U.
This work was supported by National Institutes of Health Grants GM38213, P01-HL034322, and the National












DMEM Dulbecco’s modified Eagle’s medium
rP2Y14-R rat homolog of the P2Y14-R
References
Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother
1959;14:48–58. [PubMed: 13651579]
Ault AD, Broach JR. Creation of GPCR-based chemical sensors by directed evolution in yeast. Protein
Eng Des Sel 2006;19:1–8. [PubMed: 16263727]
Besada P, Shin DH, Costanzi S, Ko H, Mathe C, Gagneron J, Gosselin G, Maddileti S, Harden TK,
Jacobson KA. Structure-activity relationships of uridine 5′-diphosphate analogues at the human
P2Y6 receptor. J Med Chem 2006;49:5532–5543. [PubMed: 16942026]
Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK. Purification and functional
reconstitution of the human P2Y12 receptor. Mol Pharmacol 2003;64:1210–1216. [PubMed:
14573771]
Bogdanov YD, Wildman SS, Clements MP, King BF, Burnstock G. Molecular cloning and
characterization of rat P2Y4 nucleotide receptor. Br J Pharmacol 1998;124:428–430. [PubMed:
9647463]
Boyer JL, Siddiqi S, Fischer B, Romero-Avila T, Jacobson KA, Harden TK. Identification of potent
P2Y-purinocepter agonists that are derivatives of adenosine 5′-monophosphate. Br J Pharmacol
1996;118:1959–1964. [PubMed: 8864529]
Burnstock G. Purinergic signaling. Br J Pharmacol 2006;147:S172–S187. [PubMed: 16402102]
Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM,
Murdock P, McMillan L, et al. A G protein-coupled receptor for UDP-glucose. J Biol Chem
2000;275:10767–10771. [PubMed: 10753868]
Communi D, Parmentier M, Boynaems JM. Cloning, functional expression and tissue distribution of
the human P2Y6 receptor. Biochem Biophys Res Commun 1996;222:303–308. [PubMed: 8670200]
Fricks et al. Page 8













Communi D, Govaerts C, Parmentier M, Boynaems JM. Cloning of a human purinergic P2Y receptor
coupled to phospholipase C and adenylyl cyclase. J Biol Chem 1997;272:31969–31973. [PubMed:
9405388]
Coward P, Chan SD, Wada HG, Humphries GM, Conklin BR. Chimeric G proteins allow a high-
throughput signaling assay of Gi-coupled receptors. Anal Biochem 1999;270:242–248. [PubMed:
10334841]
Cusack NJ, Hourani SM. Competitive inhibition by adenosine 5′-triphosphate of the actions on human
platelets of 2-chloroadenosine 5′-diphosphate, 2-azidoadenosine 5′-diphosphate and 2-
methylthioadenosine 5′-diphosphate. Br J Pharmacol 1982;77:329–333. [PubMed: 7139191]
Freeman K, Tsui P, Moore D, Emson PC, Vawter L, Naheed S, Lane P, Bawagan H, Herrity N,
Murphy K, et al. Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor
GPR105 (KIAA0001) rodent orthologs. Genomics 2001;78:124–128. [PubMed: 11735218]
Fumagalli M, Brambilla R, D’Ambrosi N, Volonte C, Matteoli M, Verderio C, Abbracchio MP.
Nucleotide-mediated calcium signaling in rat cortical astrocytes: role of P2X and P2Y receptors.
Glia 2003;43:218–223. [PubMed: 12898701]
Herold CL, Qi AD, Harden TK, Nicholas RA. Agonist versus antagonist action of ATP at the P2Y4
receptor is determined by the second extracellular loop. J Biol Chem 2004;279:11456–11464.
[PubMed: 14670966]
Houston D, Ohno M, Nicholas RA, Jacobson KA, Harden TK. [32P]2-iodo-N6-methyl-(N)-
methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate ([32P]MRS2500), a novel radioligand for
quantification of native P2Y1 receptors. Br J Pharmacol 2006;147:459–467. [PubMed: 16299552]
Houston D, Costanzi S, Jacobson KA, Harden TK. Development of selective high affinity antagonists,
agonists, and radioligands for the P2Y1 receptor. Combinatorial Chemistry & High-Throughput
Screening. 2008 in press.
Idzko M, Panther E, Sorichter S, Herouy Y, Berod L, Geissler M, Mockenhaupt M, Elsner P,
Girolomoni G, Norgauer J. Characterization of the biological activities of uridine diphosphates in
human dendritic cells: influence on chemotaxis and CXCL8 release. J Cell Physiol 2004;201:286–
293. [PubMed: 15334663]
Ivanov AA, Ko H, Cosyn L, Maddileti S, Besada P, Fricks I, Costanzi S, Harden TK, Van Calenbergh
S, Jacobson KA. Molecular modeling of the human P2Y2 receptor and design of a selective
agonist, 2′-amino-2′-deoxy-2-thiouridine 5′-triphosphate. J Med Chem 2007;50:1166–1176.
[PubMed: 17302398]
Jacobson KA, Costanzi S, Ivanov AA, Tchilibon S, Besada P, Gao ZG, Maddileti S, Harden TK.
Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5′-
triphosphate analogues at the human P2Y2 and P2Y4 receptors. Biochem Pharmacol 2006;71:540–
549. [PubMed: 16359641]
Kennedy C, Qi AD, Herold CL, Harden TK, Nicholas RA. ATP, an agonist at the rat P2Y4 receptor, is
an antagonist at the human P2Y4 receptor. Mol Pharmacol 2000;57:926–931. [PubMed:
10779375]
Ko H, Fricks I, Ivanov AA, Harden TK, Jacobson KA. Structure activity of uridine 5′-
diphosphoglucose (UDP-glucose) analogues as agonists of the human P2Y14 receptor. J Med
Chem 2007;50:2030–2039. [PubMed: 17407275]
Lazarowski ER, Harden TK. Identification of a uridine nucleotide-selective G-protein-linked receptor
that activates phospholipase C. J Biol Chem 1994;269:11830–11836. [PubMed: 8163481]
Lazarowski ER, Shea DA, Boucher RC, Harden TK. Release of cellular UDP-glucose as a potential
extracellular signaling molecule. Mol Pharmacol 2003;63:1190–1197. [PubMed: 12695547]
Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, Emson PC, Murdock PR.
Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-
polymerase chain reaction study. Biochim Biophys Acta 2001;1521:107–119. [PubMed:
11690642]
Müller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow JC Jr,
Luttmann W, Norgauer J, et al. The P2Y14 receptor of airway epithelial cells: coupling to
intracellular Ca2+ and IL-8 secretion. Am J Respir Cell Mol Biol 2005;33:601–609. [PubMed:
16109883]
Fricks et al. Page 9













Nakahata N, Harden TK. Regulation of inositol trisphosphate accumulation by muscarinic cholinergic
and H1-histamine receptors on human astrocytoma cells. Differential induction of desensitization
by agonists. Biochem J 1987;241:337–344. [PubMed: 3593197]
Nicholas RA, Watt WC, Lazarowski ER, Li Q, Harden TK. Uridine nucleotide selectivity of three
phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and
an ATP- and UTP-specific receptor. Mol Pharmacol 1996;50:224–229. [PubMed: 8700127]
Pendergast W, Yerxa BR, Douglass JG 3rd, Shaver SR, Dougherty RW, Redick CC, Sims IF, Rideout
JL. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5′-polyphosphates.
Bioorg Med Chem Lett 2001;11:157–160. [PubMed: 11206448]
Qi AD, Kennedy C, Harden TK, Nicholas RA. Differential coupling of the human P2Y11 receptor to
phospholipase C and adenylyl cyclase. Br J Pharmacol 2001;132:318–326. [PubMed: 11156592]
Roberts VH, Greenwood SL, Elliott AC, Sibley CP, Waters LH. Purinergic receptors in human
placenta: evidence for functionally active P2X4, P2X7, P2Y2, and P2Y6. Am J Physiol Regul
Integr Comp Physiol 2006;290:R1374–R1386. [PubMed: 16373435]
Scrivens M, Dickenson JM. Functional expression of the P2Y14 receptor in murine T-lymphocytes. Br
J Pharmacol 2005;146:435–444. [PubMed: 15997228]
Scrivens M, Dickenson JM. Functional expression of the P2Y14 receptor in human neutrophils. Eur J
Pharmacol 2006;543:166–173. [PubMed: 16820147]
Skelton L, Cooper M, Murphy M, Platt A. Human immature monocyte-derived dendritic cells express
the G protein-coupled receptor GPR105 (KIAA0001, P2Y14) and increase intracellular calcium in
response to its agonist, uridine diphosphoglucose. J Immunol 2003;171:1941–1949. [PubMed:
12902497]
Warny M, Aboudola S, Robson SC, Sevigny J, Communi D, Soltoff SP, Kelly CP. P2Y6 nucleotide
receptor mediates monocytes interleukin-8 production in response to UDP or lipopolysaccharide. J
Biol Chem 2001;276:26051–26056. [PubMed: 11349132]
Wihlborg AK, Balogh J, Wang L, Borna C, Dou Y, Joshi BV, Lazarowski E, Jacobson KA, Arner A,
Erlinge D. Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphates
(UDP) via P2Y2 and P2Y6 receptors on cardiomyocytes and release of UTP in man during
myocardial infarction. Circ Res 2006;98:970–976. [PubMed: 16543499]
Fricks et al. Page 10














hP2Y14-R- and Gαq/i-dependent increases in [3H]inositol phosphate accumulation. COS-7
cells were transfected with empty vector or expression vectors for hP2Y14-R and/or Gαq/i as
described under Materials and Methods. Cells were labeled with [3H]inositol for 18 h before
assay. LiCl (10 mM) buffer was added to the cells to inhibit inositol monophosphatase, and
the cells were simultaneously incubated in the absence or presence of 10 μM UDP-Glc for
45 min. [3H]Inositol phosphates were isolated as described under Materials and Methods.
The data shown are the means ± S.E. calculated from triplicate samples and are
representative of the results obtained in three independent experiments.
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Coexpression of ENPP1 reduces the basal activation of the hP2Y14-R. COS-7 cells were
cotransfected with expression vectors for hP2Y14-R and Gαq/i with (+) or without (−) an
expression vector for ENPP1. A, [3H]inositol-labeled cells were incubated with 10 mM LiCl
in the absence or presence of UDP-Glc.*, p < 0.01. B, [3H]inositol-labeled cells were
incubated with 10 mM LiCl in the absence or presence of UDP-Glc at the indicated
concentrations. The data shown are the means ± S.E. calculated from triplicate
determinations.
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UDP is a competitive antagonist at the hP2Y14-R. A, [3H]inositol-labeled COS-7 cells
coexpressing hP2Y14-R and Gαq/i were incubated with LiCl (10 mM) and increasing
concentrations of UDP-glucose in the absence or presence of the indicated concentrations of
UDP: ■, buffer; ▲, 0.1 μM; ▼, 0.3 μM; ◆, 1 μM; ●, 3 μM; □, 30 μM; and ▽, 100 μM.
Data shown are the means ± S.E. calculated from triplicate samples and are representative of
the results obtained in three independent experiments. B, EC50 values from the
concentration-effect curves in A were used for Schild regression analysis. The data shown
are results from a representative experiment repeated three times to yield a mean pKB of
7.28 ± 0.04 and a slope of 1.15 ± 0.06.
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UDP is a selective antagonist at the hP2Y14-R. [3H]Inositol-labeled 1321N1 human
astrocytoma cells stably expressing either the human P2Y1-R (A), human P2Y2-R (B),
human P2Y4-R (C), or human P2Y11-R (D) were incubated for 30 min with 10 mM LiCl
with the cognate agonist (indicated), or 10 μM UDP, or both agonist and UDP, and inositol
phosphate accumulation was quantified as described under Materials and Methods. The data
shown are the means ± S.E. calculated from triplicate samples and are representative of the
results obtained in three or more independent experiments.
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UDP is unique among nucleoside diphosphates for its antagonist effect at the hP2Y14-R.
CDP (A), ADP (B), GDP (C), or UDP (D) (10 or 100 μM) and LiCl (10 mM) were applied
simultaneously with 3 μM UDP-Glc to [3H]inositol-labeled COS-7 cells transiently
expressing hP2Y14-R and Gαq/i. Data were normalized to values from maximal activation of
hP2Y14-R by UDP-Glc alone, and the LiCl alone value was subtracted from each data point.
The data shown in A, C, and D are results from a representative experiment repeated three
times. The data shown in B are the average of results from four experiments.
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Antagonist effect of UDPβS at the hP2Y14-R. [3H]Inositol-labeled COS-7 cells transiently
expressing hP2Y14-R and Gαq/i were incubated with 10 mM LiCl in the absence (○) or
presence (●) of 1 μM UDP-Glc in the presence of the indicated concentrations of UDPβS for
30 min. The data shown are the means ± S.E. of triplicate determinations, and the results are
representative of those obtained in three experiments.
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Agonist effect of UDP-Glc and UDP at the rP2Y14-R. A, COS-7 cells transfected with an
expression vector for Gαq/i and with empty vector or rP2Y14-R were [3H]inositol-labeled
and incubated with 10 mM LiCl in the absence or presence of 10 μM UDP-Glc. B,
[3H]inositol-labeled COS-7 cells transiently expressing the rP2Y14-R and Gαq/i were
incubated with 10 mM LiCl and UDP-Glc or UDP at the indicated concentrations, and
[3H]inositol phosphate accumulation was quantified as described under Materials and
Methods. The data shown are the means ± S.E. calculated from triplicate samples and are
results from a representative experiment repeated three times, yielding an EC50 of 0.28 ±
0.05 μM for UDP-Glc and 0.35 ± 0.17 μM for UDP. Data were normalized to the maximal
activation of rP2Y14-R by UDP-Glc. C, cells incubated with UDP-Glc (10 μ M) + UDP (100
μM) exhibited no difference in [3H]inositol phosphate accumulation compared to
accumulation in the presence of either agonist alone. The data shown are the means ± S.E.
calculated from triplicate samples and are representative of results obtained in three
independent experiments.
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